COMMUNIQUÉS West-GlobeNewswire

Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
04/11/2025
Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds 100% diabetic wound closure in ≤ 12 weeks Preclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE [...]
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
04/11/2025
NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the [...]
Repligen Corporation to Present at Upcoming November Conferences
04/11/2025
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming [...]
Bioventus Reports Third Quarter Financial Results
04/11/2025
Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8% Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per [...]
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
04/11/2025
SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate cancer) [...]
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
04/11/2025
WAYNE, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients [...]
BridgeBio to Participate in November Investor Conferences
04/11/2025
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that [...]
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
04/11/2025
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Erasca to Present at Upcoming Conferences in November
04/11/2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Certara Automates Scientific Workflows with Phoenix® Cloud
04/11/2025
New cloud capabilities cut time to create Tables, Figures, and Listings by 50% RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today [...]
Jasper Therapeutics to Present at Upcoming Investor Conferences
04/11/2025
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Exagen Inc. Reports Strong Q3 2025 Results
04/11/2025
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent [...]
Alumis to Participate in Upcoming November Investor Conferences
04/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today [...]
Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
04/11/2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, [...]
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
04/11/2025
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed [...]
National Committee for Quality Assurance (NCQA) Renews Healthmap Solutions’ Population Health Program Accreditation
04/11/2025
TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Healthmap Solutions, Inc. (Healthmap) announced today that it has earned a three-year renewal of its NCQA Population Health Program Accreditation for its Kidney Population [...]
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
04/11/2025
ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved to treat [...]
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
04/11/2025
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
04/11/2025
New deal builds on the success of a longstanding partnership in retinal health and the potential of CDR-Life’s unique antibody fragment-based platform Agreement provides potential for up to approx. USD 570 million in  [...]

Pages